Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$0.6 - $1.65 $5,193 - $14,282
8,656 New
8,656 $6,000
Q2 2023

Aug 08, 2023

BUY
$2.83 - $4.94 $14,314 - $24,986
5,058 Added 17.92%
33,287 $94,000
Q1 2023

May 12, 2023

BUY
$4.89 - $12.27 $117,526 - $294,897
24,034 Added 572.92%
28,229 $138,000
Q4 2022

Feb 13, 2023

BUY
$8.88 - $12.77 $37,251 - $53,570
4,195 New
4,195 $45,000
Q2 2022

Aug 09, 2022

SELL
$7.45 - $13.84 $17,373 - $32,274
-2,332 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$9.94 - $12.65 $107,491 - $136,797
-10,814 Reduced 82.26%
2,332 $28,000
Q4 2021

Feb 11, 2022

BUY
$11.99 - $18.14 $157,620 - $238,468
13,146 New
13,146 $160,000
Q3 2021

Nov 09, 2021

SELL
$11.55 - $16.06 $25,398 - $35,315
-2,199 Closed
0 $0
Q2 2021

Aug 12, 2021

SELL
$12.38 - $29.19 $10,683 - $25,190
-863 Reduced 28.18%
2,199 $31,000
Q1 2021

May 14, 2021

BUY
$15.07 - $21.71 $45,014 - $64,847
2,987 Added 3982.67%
3,062 $66,000
Q4 2020

Feb 12, 2021

SELL
$12.72 - $16.16 $24,104 - $30,623
-1,895 Reduced 96.19%
75 $1,000
Q3 2020

Nov 16, 2020

BUY
$12.34 - $17.92 $24,309 - $35,302
1,970 New
1,970 $25,000
Q1 2020

May 13, 2020

SELL
$9.12 - $17.78 $88,090 - $171,737
-9,659 Closed
0 $0
Q4 2019

Feb 10, 2020

BUY
$16.11 - $25.98 $155,606 - $250,940
9,659 New
9,659 $155,000
Q3 2018

Nov 13, 2018

SELL
$17.57 - $23.95 $68,487 - $93,357
-3,898 Closed
0 $0
Q2 2018

Aug 13, 2018

BUY
$11.6 - $19.27 $45,216 - $75,114
3,898 New
3,898 $74,000
Q4 2017

Feb 12, 2018

SELL
$11.86 - $14.08 $11,717 - $13,911
-988 Closed
0 $0
Q3 2017

Nov 07, 2017

BUY
$12.6 - $16.34 $12,448 - $16,143
988
988 $13,000

Others Institutions Holding CARA

About Cara Therapeutics, Inc.


  • Ticker CARA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,725,900
  • Market Cap $14.5M
  • Description
  • Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...
More about CARA
Track This Portfolio

Track Quantbot Technologies LP Portfolio

Follow Quantbot Technologies LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quantbot Technologies LP, based on Form 13F filings with the SEC.

News

Stay updated on Quantbot Technologies LP with notifications on news.